Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2020 10/21/2020 10/22/2020 10/23/2020 10/26/2020 Date
576.63(c) 572.4(c) 575.73(c) 579.81(c) 585.685 Last
637 682 493 964 468 945 565 966 305 807 Volume
-1.12% -0.73% +0.58% +0.71% +1.01% Change
More quotes
Financials (USD)
Sales 2020 8 278 M - -
Net income 2020 2 973 M - -
Net cash position 2020 5 675 M - -
P/E ratio 2020 21,3x
Yield 2020 -
Sales 2021 9 889 M - -
Net income 2021 3 680 M - -
Net cash position 2021 9 710 M - -
P/E ratio 2021 16,5x
Yield 2021 -
Capitalization 61 014 M 61 014 M -
EV / Sales 2020 6,68x
EV / Sales 2021 5,19x
Nbr of Employees 8 142
Free-Float 83,3%
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (61.5%); - supply of collaborative services (33.3%): working with Sanofi (54.5% of sales) and Bayer (45.5%); - sales of technology licenses (5.2%). The group also provides subcontracting... 
More about the company
Notations Surperformance© of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
All news about REGENERON PHARMACEUTICALS
10/24To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
DJ
10/22Covid-19 Drug Remdesivir Fully Approved by FDA
DJ
10/21SCOTT+SCOTT ATTORNEYS AT LAW LLP : Continues to Investigate Regeneron Pharmaceut..
BU
10/21Lilly hires external adviser for COVID-19 drug plant problems
RE
10/21REGENERON PHARMACEUTICALS : Lilly hires external adviser for COVID-19 drug plant..
RE
10/19REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent for Children Ag..
AQ
10/19SANOFI : - CHMP recommends approval of Dupixent for children aged 6 to 11 years ..
AQ
10/19EVOTEC : secures grant to evaluate antibody drugs for COVID-19
RE
10/16REGENERON PHARMACEUTICALS : Sanofi Get CHMP Backing for Dupixent in Children Wit..
DJ
10/16REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent® (dupilumab) fo..
PR
10/15Gilead questions WHO study that cast doubts on drug's COVID-19 benefits
RE
10/15REGENERON PHARMACEUTICALS : Antibody Cocktail REGN-EB3 is First FDA-Approved Tre..
AQ
10/15REGENERON PHARMACEUTICALS : What is an antibody cocktail and what trials are bei..
AQ
10/14REGENERON PHARMACEUTICALS : drug becomes first FDA-approved Ebola virus treatmen..
RE
10/14REGENERON PHARMACEUTICALS : Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-A..
PR
More news
News in other languages on REGENERON PHARMACEUTICALS
10/13SANOFI : annonce des résultats positifs pour Dupixent dans l'asthme sévère chez ..
10/13Takeda-Gruppe beginnt mit Herstellung von Plasmabehandlung
10/08REGENERON PHARMACEUTICALS : Trump s'exprimera samedi en public à la Maison blanc..
10/08Aktien New York Schluss: Hoffnung auf Konjunkturhilfe treibt weiter an
10/08Aktien New York: Weitere Gewinne - IBM triumphiert im Dow
More news
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 671,83 $
Last Close Price 579,81 $
Spread / Highest target 38,0%
Spread / Average Target 15,9%
Spread / Lowest Target -13,8%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Patrice Gilooly Senior VP-Quality Assurance & Operations
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS54.42%61 014
GILEAD SCIENCES, INC.-6.45%76 214
VERTEX PHARMACEUTICALS-3.37%55 110
WUXI APPTEC CO., LTD.58.33%37 775
BEIGENE, LTD.80.38%27 097
GENMAB A/S49.17%22 988